Info

SBI is a privately-held proteomics-driven drug discovery company utilizing proprietary technologies for accelerating and optimizing the drug discovery process. SBI incorporates these technologies to advance its own drug pipeline, and concurrently markets them to pharmaceutical and to other drug discovery-focused biotech companies. SBI's internal drug discovery programs are focused on diabetes, cancer, inflammation and infectious diseases. SBI's Genes to Leads® technology produces drug leads in as little as 60 days , with an efficiency that is more than 1,000-fold greater than high-throughput screening. SBI is headquartered in San Diego, CA, with offices in Cambridge, MA; Washington, D.C. and Hørsholm, Denmark.